DE602004027936D1 - Tocopherolmodifizierte therapeutische arzneimittelverbindung - Google Patents
Tocopherolmodifizierte therapeutische arzneimittelverbindungInfo
- Publication number
- DE602004027936D1 DE602004027936D1 DE602004027936T DE602004027936T DE602004027936D1 DE 602004027936 D1 DE602004027936 D1 DE 602004027936D1 DE 602004027936 T DE602004027936 T DE 602004027936T DE 602004027936 T DE602004027936 T DE 602004027936T DE 602004027936 D1 DE602004027936 D1 DE 602004027936D1
- Authority
- DE
- Germany
- Prior art keywords
- tocopherol
- therapeutic drug
- modified therapeutic
- compounds
- drug compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51536403P | 2003-10-29 | 2003-10-29 | |
US55613704P | 2004-03-24 | 2004-03-24 | |
US55876204P | 2004-04-01 | 2004-04-01 | |
US62165504P | 2004-10-26 | 2004-10-26 | |
PCT/US2004/036127 WO2005042539A1 (en) | 2003-10-29 | 2004-10-29 | Tocopherol-modified therapeutic drug compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004027936D1 true DE602004027936D1 (de) | 2010-08-12 |
Family
ID=34557676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004027936T Active DE602004027936D1 (de) | 2003-10-29 | 2004-10-29 | Tocopherolmodifizierte therapeutische arzneimittelverbindung |
Country Status (12)
Country | Link |
---|---|
US (3) | US7223770B2 (de) |
EP (1) | EP1682552B1 (de) |
JP (1) | JP2007509978A (de) |
KR (1) | KR20060110872A (de) |
AT (1) | ATE472551T1 (de) |
AU (1) | AU2004285037B2 (de) |
BR (1) | BRPI0415858A (de) |
CA (1) | CA2543722C (de) |
DE (1) | DE602004027936D1 (de) |
IL (1) | IL175158A0 (de) |
TW (1) | TW200522978A (de) |
WO (1) | WO2005042539A1 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
NZ554677A (en) * | 2004-11-05 | 2010-08-27 | Samyang Corp | Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents |
GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
PL3248600T3 (pl) | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
KR20130079645A (ko) * | 2005-07-18 | 2013-07-10 | 유니버시티 오브 메사츄세츠 로웰 | 나노에멀젼 조성물 및 이의 제조 및 사용 방법 |
AU2016244292A1 (en) * | 2005-07-18 | 2016-11-03 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
WO2007035311A2 (en) * | 2005-09-16 | 2007-03-29 | University Of Massachusetts Lowell | Anti-oxidant synergy formulation nanoemulsions to treat cancer |
US7572610B2 (en) * | 2005-10-03 | 2009-08-11 | Biotechnology Research & Development Corporation | Methods of making compositions comprising a UV-Absorbing chromophore |
US7727514B2 (en) * | 2005-10-03 | 2010-06-01 | Biotechnology Research & Development Corporation | Compositions comprising a UV-absorbing chromophore |
US7744856B2 (en) * | 2005-10-03 | 2010-06-29 | Biotech Research And Development Corporation | Formulations with feruloyl glycerides and methods of preparation |
EP3295955B1 (de) | 2005-12-01 | 2021-04-07 | University Of Massachusetts Lowell | Botulinum-nanoemulsionen |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US7786134B2 (en) * | 2005-12-16 | 2010-08-31 | Sonus Pharmaceuticals, Inc. | Lipophilic anticancer drug compounds, compositions and related methods |
CZ300305B6 (cs) * | 2005-12-20 | 2009-04-15 | Heaton, A. S. | Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
TWI376239B (en) * | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
AU2007264975A1 (en) * | 2006-06-29 | 2008-01-03 | Biotech Research And Development Corporation | Formulations with feruloyl glycerides and methods of preparation |
WO2008016664A2 (en) * | 2006-08-02 | 2008-02-07 | University Of Massachusetts Lowell | Compositions and methods for treating cancer with dacarbazine nanoemulsions |
BRPI0719756A2 (pt) | 2006-12-01 | 2014-01-21 | Anterios Inc | Nanopartículas de entidades anfifílicas |
JP5292304B2 (ja) * | 2006-12-01 | 2013-09-18 | アンテリオス, インコーポレイテッド | ペプチドナノ粒子およびその使用 |
US10016451B2 (en) | 2007-05-31 | 2018-07-10 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
AU2008269179A1 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without Tween 80 |
EP2222278B1 (de) | 2007-11-28 | 2015-04-08 | Celator Pharmaceuticals, Inc. | Verbessertes taxan-abgabesystem |
EP2548456B1 (de) | 2008-03-20 | 2015-07-08 | Virun, Inc. | Emulsionen mit einem PEG-Derivat von Tocopherol |
CN102036661B (zh) * | 2008-03-20 | 2016-12-28 | 维尔恩公司 | 维生素衍生物及其用途 |
US7670894B2 (en) * | 2008-04-30 | 2010-03-02 | Intel Corporation | Selective high-k dielectric film deposition for semiconductor device |
KR102080429B1 (ko) * | 2008-06-26 | 2020-02-21 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
WO2010124223A1 (en) * | 2009-04-23 | 2010-10-28 | First Tech International Limited | Anti-cancer tocotrienol analogues and associated methods |
EP2473044B1 (de) * | 2009-09-01 | 2014-04-02 | First Tech International Limited | Tocotrienolzusammensetzungen |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
WO2011097481A1 (en) * | 2010-02-05 | 2011-08-11 | First Tech International Limited | Tocotrienol esters |
WO2011103512A1 (en) * | 2010-02-18 | 2011-08-25 | Martek Biosciences Corporation | Dha free fatty acid emulsions |
US9320295B2 (en) * | 2010-03-23 | 2016-04-26 | Virun, Inc. | Compositions containing non-polar compounds |
MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
WO2011153010A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Biosciences, Llc | Methods of treatment of pancreatic cancer |
US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
US9731025B2 (en) | 2010-08-20 | 2017-08-15 | National University Corporation Tokyo Medical And Dental University | Pharmaceutical composition for transcolonic absorption |
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
CN102516258B (zh) * | 2011-11-11 | 2014-06-25 | 正大天晴药业集团股份有限公司 | 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用 |
WO2013120025A1 (en) | 2012-02-10 | 2013-08-15 | Virun, Inc. | Beverage compositions containing non-polar compounds |
CN102731518B (zh) * | 2012-06-26 | 2014-12-03 | 济南精合医药科技有限公司 | 用于抗肿瘤药物的邻硝基芳甲氧基喜树碱缺氧激活前药 |
CN102731519B (zh) * | 2012-06-26 | 2014-12-17 | 济南精合医药科技有限公司 | 用于抗肿瘤药物的对硝基芳甲氧基喜树碱缺氧激活前药 |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9351517B2 (en) | 2013-03-15 | 2016-05-31 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and compositions containing same |
US20140314672A1 (en) * | 2013-04-06 | 2014-10-23 | Igdrasol, Inc. | Nanoparticle therapeutic agents, their formulations, and methods of their use |
US20150147382A1 (en) * | 2013-09-23 | 2015-05-28 | Exir Nano Sina Company | Topical liposomal compositions for delivering hydrophobic drugs and methods preparing same |
CA2947741A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
WO2015171924A2 (en) * | 2014-05-07 | 2015-11-12 | Cornell University | Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them |
JP2017526623A (ja) | 2014-06-18 | 2017-09-14 | テティス・ファーマシューティカルズ・エルエルシー | 活性物質のミネラル・アミノ酸錯体 |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
US9861611B2 (en) | 2014-09-18 | 2018-01-09 | Virun, Inc. | Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same |
EP3204004A4 (de) * | 2014-10-08 | 2018-05-30 | Epigenetics Pharma LLC | Vitamin-e-nukleosidprodrugs |
CN105777770B (zh) * | 2014-12-26 | 2018-05-25 | 中国人民解放军第二军医大学 | 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体 |
CN104800858B (zh) * | 2015-04-27 | 2017-11-21 | 中国医学科学院基础医学研究所 | Hsp90抑制肽偶联物及其在肿瘤治疗中的应用 |
GB2550346B (en) * | 2016-05-13 | 2021-02-24 | Phytoceutical Ltd | Micelles |
WO2017210604A1 (en) | 2016-06-03 | 2017-12-07 | Thetis Pharmaceuticals Llc | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
JP2019530737A (ja) | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
MX2021003116A (es) * | 2018-09-17 | 2021-05-14 | Childrens Hospital Philadelphia | Profarmacos macromoleculares a base de polimero. |
KR20220157944A (ko) | 2020-02-21 | 2022-11-29 | 아카우오스, 인크. | 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법 |
CA3231432A1 (en) | 2021-10-15 | 2023-04-20 | Tianyi Ke | Composition containing antitumor drug, and preparation method therefor and use thereof |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1395994A (en) | 1972-08-23 | 1975-05-29 | Delmar Chem | Tocopherol derivative processes for making it and pharmaceutical compositions containing it |
GB1409612A (en) | 1973-09-13 | 1975-10-08 | Ahrens G W | Phenylpropyl-d-alpha-tocopherol-succinate the method for making the same and preparations |
WO1979000401A1 (en) | 1977-12-16 | 1979-07-12 | Nisshin Flour Milling Co | Anti-tumor agent |
JPS5484034A (en) * | 1977-12-16 | 1979-07-04 | Nisshin Flour Milling Co Ltd | Anti-tumor agent |
US4665204A (en) | 1985-06-27 | 1987-05-12 | Henkel Corporation | Diester derivatives of tocopherol |
US5610180A (en) | 1988-01-29 | 1997-03-11 | Virginia Commonwealth University | Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents |
US5234695A (en) | 1990-07-24 | 1993-08-10 | Eastman Kodak Company | Water dispersible vitamin E composition |
JP3644543B2 (ja) | 1993-10-22 | 2005-04-27 | ヘクサル・アーゲー | シクロスポリンA及びα−トコフェロールを含有する医薬組成物 |
GB9409778D0 (en) | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
CA2148148A1 (en) | 1994-05-20 | 1995-11-21 | Kazumi Ogata | Tocopherol derivatives |
DE4423915A1 (de) | 1994-07-07 | 1996-01-11 | Carl Heinrich Dr Weischer | Derivate des Salazosulfapyridins, deren Herstellung und Verwendung als Arzneimittel |
US5858398A (en) | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
US5945409A (en) | 1995-03-10 | 1999-08-31 | Wilson T. Crandall | Topical moisturizing composition and method |
US5912078A (en) * | 1996-05-02 | 1999-06-15 | Milliken & Company | Lubricant finish for textiles |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
EP0914116B1 (de) * | 1996-05-22 | 2000-10-11 | Protarga Inc. | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten |
US6576636B2 (en) | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
US5919815A (en) | 1996-05-22 | 1999-07-06 | Neuromedica, Inc. | Taxane compounds and compositions |
AU735648B2 (en) * | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
US6727280B2 (en) | 1997-01-07 | 2004-04-27 | Sonus Pharmaceuticals, Inc. | Method for treating colorectal carcinoma using a taxane/tocopherol formulation |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
GB9715759D0 (en) | 1997-07-26 | 1997-10-01 | Danbiosyst Uk | New emulsion formulations |
AU1172599A (en) | 1997-11-18 | 1999-06-07 | Chugai Seiyaku Kabushiki Kaisha | Compounds with antitumor activity |
US5917060A (en) | 1997-12-17 | 1999-06-29 | Basf Aktiengesellschaft | Preparation of chromanyl derivatives |
DE69805334T2 (de) | 1997-12-24 | 2002-12-05 | Senju Pharma Co | Derivate des vitamin e |
US6086915A (en) * | 1998-04-01 | 2000-07-11 | Bioresponse L.L.C. | Compositions and methods of adjusting steroid hormone metabolism through phytochemicals |
AU757013B2 (en) | 1998-09-23 | 2003-01-30 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
US6045826A (en) | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
AU5273200A (en) * | 1999-05-24 | 2000-12-12 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
WO2000077085A1 (en) * | 1999-06-11 | 2000-12-21 | Sydney Hyman | Image making medium |
CA2385989A1 (en) * | 1999-09-27 | 2001-04-05 | Andrew Nienstedt | Compositions of tocol-soluble therapeutics |
US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
WO2002076970A2 (en) * | 2001-03-23 | 2002-10-03 | Sonus Pharmaceuticals, Inc. | Tocopherol succinate derivatives and compositions |
US6774116B2 (en) * | 2001-04-17 | 2004-08-10 | Cryolife, Inc. | Prodrugs via acylation with cinnamate |
US6858227B1 (en) * | 2001-11-21 | 2005-02-22 | Sonus Pharmaceuticals, Inc. | Vitamin E conjugates |
US6683194B2 (en) | 2002-02-05 | 2004-01-27 | Sonus Pharmaceuticals, Inc. | Tocopherol derivatives |
-
2004
- 2004-10-29 BR BRPI0415858-0A patent/BRPI0415858A/pt not_active IP Right Cessation
- 2004-10-29 DE DE602004027936T patent/DE602004027936D1/de active Active
- 2004-10-29 JP JP2006538354A patent/JP2007509978A/ja active Pending
- 2004-10-29 EP EP04817489A patent/EP1682552B1/de not_active Not-in-force
- 2004-10-29 WO PCT/US2004/036127 patent/WO2005042539A1/en active Application Filing
- 2004-10-29 CA CA2543722A patent/CA2543722C/en not_active Expired - Fee Related
- 2004-10-29 KR KR1020067008232A patent/KR20060110872A/ko not_active Application Discontinuation
- 2004-10-29 TW TW093132975A patent/TW200522978A/zh unknown
- 2004-10-29 AU AU2004285037A patent/AU2004285037B2/en not_active Ceased
- 2004-10-29 AT AT04817489T patent/ATE472551T1/de not_active IP Right Cessation
- 2004-10-29 US US10/978,222 patent/US7223770B2/en not_active Expired - Fee Related
-
2006
- 2006-04-25 IL IL175158A patent/IL175158A0/en unknown
- 2006-06-08 US US11/450,795 patent/US20060229359A1/en not_active Abandoned
-
2007
- 2007-03-22 US US11/690,005 patent/US20070207196A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7223770B2 (en) | 2007-05-29 |
JP2007509978A (ja) | 2007-04-19 |
AU2004285037B2 (en) | 2010-07-22 |
US20050096340A1 (en) | 2005-05-05 |
US20070207196A1 (en) | 2007-09-06 |
ATE472551T1 (de) | 2010-07-15 |
TW200522978A (en) | 2005-07-16 |
CA2543722C (en) | 2011-01-04 |
KR20060110872A (ko) | 2006-10-25 |
BRPI0415858A (pt) | 2007-01-09 |
CA2543722A1 (en) | 2005-05-12 |
US20060229359A1 (en) | 2006-10-12 |
EP1682552B1 (de) | 2010-06-30 |
EP1682552A1 (de) | 2006-07-26 |
AU2004285037A1 (en) | 2005-05-12 |
WO2005042539A1 (en) | 2005-05-12 |
IL175158A0 (en) | 2006-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
CY1107074T1 (el) | Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης | |
NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
NO20026255L (no) | Polymere micellesammensetninger | |
CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
CY1112376T1 (el) | Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2 | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
TW200603831A (en) | Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds | |
PL371736A1 (en) | Method for administering glp-1 molecules | |
TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
HK1113970A1 (en) | Formulations for injection of catecholic butanes, including ndga compounds, into animals | |
CY1106386T1 (el) | Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης | |
NO20063429L (no) | Brusende oral opiat doseringsform | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
CY1105247T1 (el) | Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης | |
MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
EA200501821A1 (ru) | Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат | |
DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
EA200501697A1 (ru) | Дозируемая форма, содержащая пантопразол в качестве активного ингредиента | |
WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof | |
CY1105317T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων |